Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgery
Published in: World Journal of Surgery 8/2018

01-08-2018 | Original Scientific Report

Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer

Authors: Hiroaki Saito, Yusuke Kono, Yuki Murakami, Yuji Shishido, Hirohiko Kuroda, Tomoyuki Matsunaga, Yoji Fukumoto, Tomohiro Osaki, Keigo Ashida, Yoshiyuki Fujiwara

Published in: World Journal of Surgery | Issue 8/2018

Login to get access

Abstract

Background

Thrombocytosis develops in association with malignant tumors and may reflect the inflammation status in cancer patients. This study retrospectively investigated the prognostic significance of two platelet-based inflammatory indicators, the platelet × C-reactive protein multiplier value (P-CRP), and platelet-lymphocyte ratio (PLR), in gastric cancer patients.

Methods

The 453 enrolled patients had a histopathological diagnosis of gastric adenocarcinoma and underwent curative surgery.

Results

P-CRP correlated significantly with age, tumor size, depth of invasion, lymph node metastasis, and disease stage. A high PLR correlated significantly with tumor size, depth of invasion, lymph node metastasis, lymphatic involvement, venous involvement, and disease stage. In the ROC analysis, the optimal cutoff value of P-CRP and PLR was 3.689 and 173.3, respectively. Five-year survival rates were 62.9 and 82.1% in patients with P-CRPHigh (≥3.689) and P-CRPLow (<3.698), respectively (P < 0.0001). Five-year survival rates were 66.3 and 81.3% in patients with PLRHigh (≥173.3) and PLRLow (<173.3), respectively (P = 0.0022). The prognosis of the P-CRPHigh/PLRHigh group was significantly worse than that of the P-CRPHigh or PLRHigh and P-CRPLow/PLRLow groups in terms of overall survival (P < 0.0001) and disease-specific survival (P = 0.029). In a multivariate analysis, the combination of P-CRP and PLR was an independent prognostic indicator.

Conclusions

The combination of P-CRP and PLR may be useful in predicting prognosis in gastric cancer patients.
Literature
1.
2.
3.
Kwon OK, Yu W, Chung H (2013) Prognostic value of postoperative CA19-9 normalization in patients with advanced gastric cancer. Hepatogastroenterology 60:240–243PubMed
4.
Kim DH, Oh SJ, Oh CA et al (2011) The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol 104:585–591CrossRefPubMed
5.
6.
Ikeguchi M, Hatada T, Yamamoto M et al (2009) Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 12:95–100CrossRefPubMed
7.
Kim DK, Oh SY, Kwon HC et al (2009) Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer 9:155CrossRefPubMedPubMedCentral
8.
Imai T, Koike K, Kubo T et al (1991) Interleukin-6 supports human megakaryocytic proliferation and differentiation in vitro. Blood 78:1969–1974PubMed
9.
Ruscetti FW (1994) Hematologic effects of interleukin-1 and interleukin-6. Curr Opin Hematol 1:210–215PubMed
10.
Ikeda M, Furukawa H, Imamura H et al (2002) Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 9:287–291CrossRefPubMed
11.
Tomita M, Shimizu T, Hara M et al (2009) Preoperative leukocytosis, anemia and thrombocytosis are associated with poor survival in non-small cell lung cancer. Anticancer Res 29:2687–2690PubMed
12.
Gorelick C, Andikyan V, Mack M et al (2009) Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an inner-city population. Int J Gynecol Cancer 19:1384–1389CrossRefPubMed
13.
Japanese Gastric Cancer Association (2011) Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 14:101–112CrossRef
14.
Bozzetti F, Bonfanti G, Morabito A et al (1986) A multifactorial approach for the prognosis of patients with carcinoma of the stomach after curative resection. Surg Gynecol Obstet 162:229–234PubMed
15.
Maruyama K (1987) The most important prognostic factors for gastric cancer patients. Scand J Gastroenterol 22:63–68CrossRef
16.
Morris-Stiff G, Gomez D, Prasad KR (2008) C-reactive protein in liver cancer surgery. Eur J Surg Oncol 34:727–729CrossRefPubMed
17.
Wu CW, Wang SR, Chao MF et al (1996) Serum interleukin-6 levels reflect disease status of gastric cancer. Am J Gastroenterol 91:1417–1422PubMed
18.
Matsuo K, Oka M, Murase K et al (2003) Expression of interleukin 6 and its receptor in human gastric and colorectal cancers. J Int Med Res 31:69–75CrossRefPubMed
19.
Yu Q, Yu XF, Zhang SD et al (2013) Prognostic role of C-reactive protein in gastric cancer: a meta-analysis. Asian Pac J Cancer Prev 14:5735–5740CrossRefPubMed
20.
Jiang X, Hiki N, Nunobe S et al (2012) Prognostic importance of the inflammation-based Glasgow prognostic score in patients with gastric cancer. Br J Cancer 107:275–279CrossRefPubMedPubMedCentral
21.
George ML, Eccles SA, Tutton MG et al (2000) Correlation of plasma and serum vascular endothelial growth factor levels with platelet count in colorectal cancer: clinical evidence of platelet scavenging? Clin Cancer Res 6:3147–3152PubMed
22.
Gunsilius E, Petzer A, Stockhammer G et al (2000) Thrombocytes are the major source for soluble vascular endothelial growth factor in peripheral blood. Oncology 58:169–174CrossRefPubMed
23.
Sierko E, Wojtukiewicz MZ (2004) Platelets and angiogenesis in malignancy. Semin Thromb Hemost 30:95–108CrossRefPubMed
24.
Mohle R, Green D, Moore MA et al (1997) Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA 94:663–668CrossRefPubMed
25.
26.
Troxler M, Dickinson K, Homer-Vanniasinkam S (2007) Platelet function and antiplatelet therapy. Br J Surg 94:674–682CrossRefPubMed
27.
Saito H, Tsujitani S, Kondo A et al (1999) Expression of vascular endothelial growth factor correlates with hematogenous recurrence in gastric carcinoma. Surgery 125:195–201CrossRefPubMed
28.
Gislason T, Nou E (1985) Sedimentation rate, leucocytes, platelet count and haemoglobin in bronchial carcinoma: an epidemiological study. Eur J Respir Dis 66:141–146PubMed
29.
Karpatkin S, Pearlstein E (1981) Role of platelets in tumor cell metastases. Ann Intern Med 95:636–641CrossRefPubMed
30.
Ishikawa F, Miyazono K, Hellman U et al (1989) Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 338:557–562CrossRefPubMed
31.
Kim EY, Lee JW, Yoo HM et al (2015) The platelet-to-lymphocyte ratio versus neutrophil-to-lymphocyte ratio: which is better as a prognostic factor in gastric cancer? Ann Surg Oncol 22:4363–4370CrossRefPubMed
32.
Zhao QT, Yuan Z, Zhang H et al (2016) Prognostic role of platelet to lymphocyte ratio in non-small cell lung cancers: a meta-analysis including 3,720 patients. Int J Cancer 139:164–170CrossRefPubMed
33.
Yodying H, Matsuda A, Miyashita M et al (2016) Prognostic significance of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: a systematic review and meta-analysis. Ann Surg Oncol 23:646–654CrossRefPubMed
34.
35.
Borghaei H, Paz-Ares L, Horn L et al (2015) Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373:1627–1639CrossRefPubMedPubMedCentral
36.
Ferris RL, Blumenschein G Jr, Fayette J et al (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856–1867CrossRefPubMedPubMedCentral
37.
Gooden MJ, de Bock GH, Leffers N et al (2011) The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer 105:93–103CrossRefPubMedPubMedCentral
38.
Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964CrossRefPubMed
39.
Tang Y, Xu X, Guo S et al (2014) An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS ONE 9:e91551CrossRefPubMedPubMedCentral
40.
Clark EJ, Connor S, Taylor MA et al (2007) Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 9:456–460CrossRef
41.
Feng JF, Liu JS, Huang Y (2014) Lymphopenia predicts poor prognosis in patients with esophageal squamous cell carcinoma. Medicine (Baltimore) 93:e257CrossRef
42.
Saroha S, Uzzo RG, Plimack ER et al (2013) Lymphopenia is an independent predictor of inferior outcome in clear cell renal carcinoma. J Urol 189:454–461CrossRefPubMed
43.
Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69:5383–5391CrossRefPubMedPubMedCentral
44.
Qiu H, Xiao-Jun W, Zhi-Wei Z et al (2009) The prognostic significance of peripheral T-lymphocyte subsets and natural killer cells in patients with colorectal cancer. Hepatogastroenterology 56:1310–1315PubMed
45.
Tachibana T, Onodera H, Tsuruyama T et al (2005) Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin Cancer Res 11:7322–7327CrossRefPubMed
46.
Berntsson J, Nodin B, Eberhard J et al (2016) Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer. Int J Cancer 139:1129–1139CrossRefPubMed
47.
Yoshikawa T, Saito H, Osaki T et al (2008) Elevated Fas expression is related to increased apoptosis of circulating CD8 + T cell in patients with gastric cancer. J Surg Res 148:143–151CrossRefPubMed
Metadata
Title
Prognostic Significance of Platelet-Based Inflammatory Indicators in Patients with Gastric Cancer
Authors
Hiroaki Saito
Yusuke Kono
Yuki Murakami
Yuji Shishido
Hirohiko Kuroda
Tomoyuki Matsunaga
Yoji Fukumoto
Tomohiro Osaki
Keigo Ashida
Yoshiyuki Fujiwara
Publication date
01-08-2018
Publisher
Springer International Publishing
Published in
World Journal of Surgery / Issue 8/2018
Print ISSN: 0364-2313
Electronic ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-018-4527-8

Other articles of this Issue 8/2018

World Journal of Surgery 8/2018 Go to the issue

Original Scientific Report

How Much Data are Good Enough? Using Simulation to Determine the Reliability of Estimating POMR for Resource-Constrained Settings

Original Scientific Report

Decision-Making in Management of the Complex Trauma Patient: Changing the Mindset of the non-trauma Surgeon

Original Scientific Report

Necrotizing Soft Tissue Infections at a Tertiary Referral Hospital in Rwanda: Epidemiology and Risk Factors for Mortality

Original Scientific Report

Wide Surgical Margin Improves the Outcome for Patients with Gastrointestinal Stromal Tumors (GISTs)

Original Scientific Report

Adrenal Ganglioneuroma: Features and Outcomes of 42 Cases in a Chinese Population

Original Scientific Report

Predictive Factors for Lymph Node Metastasis in Submucosal Invasive Colorectal Carcinoma: A New Proposal of Depth of Invasion for Radical Surgery